KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GoodRx Holdings (GDRX) Change in Accured Expenses (2019 - 2025)

GoodRx Holdings' Change in Accured Expenses history spans 7 years, with the latest figure at -$41.0 million for Q4 2025.

  • For Q4 2025, Change in Accured Expenses fell 540.59% year-over-year to -$41.0 million; the TTM value through Dec 2025 reached $1.2 million, down 88.04%, while the annual FY2025 figure was $1.2 million, 88.04% down from the prior year.
  • Change in Accured Expenses for Q4 2025 was -$41.0 million at GoodRx Holdings, down from $41.9 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $41.9 million in Q3 2025 and bottomed at -$41.0 million in Q4 2025.
  • The 5-year median for Change in Accured Expenses is $405000.0 (2023), against an average of $1.1 million.
  • The largest annual shift saw Change in Accured Expenses plummeted 25567.16% in 2022 before it soared 18695.52% in 2025.
  • A 5-year view of Change in Accured Expenses shows it stood at $8.7 million in 2021, then crashed by 189.82% to -$7.8 million in 2022, then surged by 76.86% to -$1.8 million in 2023, then skyrocketed by 615.56% to $9.3 million in 2024, then crashed by 540.59% to -$41.0 million in 2025.
  • Per Business Quant, the three most recent readings for GDRX's Change in Accured Expenses are -$41.0 million (Q4 2025), $41.9 million (Q3 2025), and $19.4 million (Q2 2025).